Ameriprise Financial Inc. bought a new position in shares of BioTime, Inc. (NYSEAMERICAN:BTX) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 45,285 shares of the biotechnology company’s stock, valued at approximately $142,000.

Other institutional investors also recently made changes to their positions in the company. Vanguard Group Inc. raised its position in BioTime by 15.1% during the first quarter. Vanguard Group Inc. now owns 3,146,178 shares of the biotechnology company’s stock valued at $10,855,000 after buying an additional 413,073 shares during the period. Schwab Charles Investment Management Inc. raised its position in BioTime by 51.7% during the second quarter. Schwab Charles Investment Management Inc. now owns 163,100 shares of the biotechnology company’s stock valued at $514,000 after buying an additional 55,600 shares during the period. Metropolitan Life Insurance Co. NY raised its position in BioTime by 14.7% during the first quarter. Metropolitan Life Insurance Co. NY now owns 57,694 shares of the biotechnology company’s stock valued at $199,000 after buying an additional 7,411 shares during the period. American International Group Inc. raised its position in BioTime by 8.3% during the first quarter. American International Group Inc. now owns 39,794 shares of the biotechnology company’s stock valued at $137,000 after buying an additional 3,036 shares during the period. Finally, Bank of New York Mellon Corp raised its position in BioTime by 17.5% during the first quarter. Bank of New York Mellon Corp now owns 445,031 shares of the biotechnology company’s stock valued at $1,535,000 after buying an additional 66,195 shares during the period.

In other news, Director Broadwood Partners, L.P. bought 2,692,307 shares of the company’s stock in a transaction on Friday, October 13th. The shares were bought at an average cost of $2.60 per share, with a total value of $6,999,998.20. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Over the last ninety days, insiders acquired 2,706,307 shares of company stock worth $7,036,478.

Several research firms recently weighed in on BTX. Zacks Investment Research raised BioTime from a “hold” rating to a “buy” rating and set a $2.75 price target on the stock in a research report on Wednesday, November 15th. BidaskClub lowered BioTime from a “sell” rating to a “strong sell” rating in a research report on Wednesday, October 18th. Two research analysts have rated the stock with a sell rating and three have assigned a buy rating to the stock. BioTime has an average rating of “Hold” and an average price target of $5.08.

BioTime, Inc. (BTX) opened at $2.50 on Monday. BioTime, Inc. has a 52-week low of $2.19 and a 52-week high of $3.97.

ILLEGAL ACTIVITY NOTICE: This report was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The legal version of this report can be viewed at https://www.watchlistnews.com/ameriprise-financial-inc-takes-142000-position-in-biotime-inc-btx/1715079.html.

BioTime Profile

BioTime, Inc is a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases. Its clinical programs are based on two platform technologies: pluripotent stem cells and cell/drug delivery platform technologies. The foundation of its cell delivery platform is its HyStem cell and drug delivery matrix technology.

Want to see what other hedge funds are holding BTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioTime, Inc. (NYSEAMERICAN:BTX).

Institutional Ownership by Quarter for BioTime (NYSEAMERICAN:BTX)

Receive News & Ratings for BioTime Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTime Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.